about
InterPro in 2011: new developments in the family and domain prediction databaseInterPro: the integrative protein signature databaseInterPro, progress and status in 2005The InterPro database, 2003 brings increased coverage and new featuresThe use of fused PET/CT images for patient selection and radical radiotherapy target volume definition in patients with non-small cell lung cancer: results of a prospective study with mature survival data.An evaluation of GO annotation retrieval for BioCreAtIvE and GOA.New developments in the InterPro database.InterPro: an integrated documentation resource for protein families, domains and functional sites.The InterPro BioMart: federated query and web service access to the InterPro Resource.UniProt archive.The GOA database in 2009--an integrated Gene Ontology Annotation resource.Harmonizing FDG PET quantification while maintaining optimal lesion detection: prospective multicentre validation in 517 oncology patients.Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent.Quantitative and qualitative analysis of [(18)F]FDG and [(18)F]FAZA positron emission tomography of head and neck cancers and associations with HPV status and treatment outcome.QuickGO: a user tutorial for the web-based Gene Ontology browser.QuickGO: a web-based tool for Gene Ontology searching.The Gene Ontology Annotation (GOA) project: implementation of GO in SWISS-PROT, TrEMBL, and InterPro.PET imaging of tumours with a 64Cu labeled macrobicyclic cage amine ligand tethered to Tyr3-octreotate.Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer.The clinical impact of (18)F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study.Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models.In vivo measurement of hippocampal GABAA/cBZR density with [18F]-flumazenil PET for the study of disease progression in an animal model of temporal lobe epilepsyHigh rates of tumor growth and disease progression detected on serial pretreatment fluorodeoxyglucose-positron emission tomography/computed tomography scans in radical radiotherapy candidates with nonsmall cell lung cancer.18F-flumazenil: a γ-aminobutyric acid A-specific PET radiotracer for the localization of drug-resistant temporal lobe epilepsy.Pulmonary tumor volume delineation in PET images using deformable models.Investigations with FDG-PET scanning in prostate cancer show limited value for clinical practice.The impact of time between staging PET/CT and definitive chemo-radiation on target volumes and survival in patients with non-small cell lung cancer.High-resolution imaging of pulmonary ventilation and perfusion with 68Ga-VQ respiratory gated (4-D) PET/CT.Validation of a 4D-PET maximum intensity projection for delineation of an internal target volume.Preclinical FLT-PET and FDG-PET imaging of tumor response to the multi-targeted Aurora B kinase inhibitor, TAK-901.Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation.F-18 PET soft tissue uptake in seatbelt injury.Automatic tumour volume delineation in respiratory-gated PET images.Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer.InterPro in 2011: new developments in the family and domain prediction database.In-vivo imaging characteristics of two fluorinated flumazenil radiotracers in the rat.Diagnostic imaging agents for Alzheimer's disease: copper radiopharmaceuticals that target Aβ plaques.Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging.An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development.Multi-tracer small animal PET imaging of the tumour response to the novel pan-Erb-B inhibitor CI-1033.
P50
Q24620144-04FAA6CD-0A45-45D0-AB92-A161BD8F0B39Q24655685-6D96BED8-E82B-47C8-84DB-A3E996689A1DQ24796722-02DB7F80-C8A2-48E0-B317-E70869761E1EQ28202393-076663C9-AF6B-476F-B551-9A7EC3821FB9Q30609124-88149104-B191-4809-8EF5-861F683CDBF5Q33217255-3CB168DF-508D-435F-A06A-7F938A39D95CQ33268110-0727B029-E1C3-4D22-85D3-4D61DF563349Q33961349-8B76B8EF-53FA-442E-81BF-2640F6F3F261Q33969854-A13370E0-7B10-457E-82E8-B5BB0D0805C9Q33976927-DD0EBE95-4525-4F29-97EF-83BAD0286C4EQ34867602-35434157-4A64-44D2-BCD2-1B0D246F5E1FQ36214863-E6E3F834-F2E6-49EF-95F5-1FA33B6233C9Q36245361-E3E870CD-97E2-4580-8BAC-8D6B706F2F10Q36619504-ACA70971-1012-485D-87C9-607490161203Q37479484-CB83206A-568D-4FB2-9FB2-217609C3E715Q38509056-C295A0D8-9021-4C35-99A7-D83DC83C4B02Q38522863-65051A1D-4F7D-4F70-A11B-14C778A1AD3DQ39066068-B05FCC76-3CBA-408B-A677-B53B5FE5AF5AQ39191502-2AA7D0EB-A720-49CA-B0CB-16ADFFB00A9DQ39222149-DA3294C7-0E92-4FDC-9A0F-2BB28F40FBEFQ39505460-C774FD2A-C688-4406-A7E3-8521C20C241FQ41882993-D566A4E5-6521-4A2A-942A-7C655AAB620DQ42972813-DD56B216-29B2-48F3-8CDA-0380A76B526BQ43675779-F9C0DE8B-F280-407F-B1C4-AD7FBC8C1130Q43746085-43160FB4-C31C-4B83-8A0E-209EAB6F84A2Q44223244-D771AA54-E18A-4484-BF44-0529C32AB826Q44361015-2B1DB4E9-6D47-45E5-88D1-2C49E2CC166BQ44518809-5F0A1599-83ED-4C43-9EBD-98C3502F9285Q44684908-E0CDF11E-C238-4057-9CC9-724E344B6DC8Q44929665-77A6CBCA-F6C3-4F46-8753-A308D53F7643Q45068481-EDFD0F6A-BBD1-4907-85AE-CD42869929E0Q45151989-7C51E2F1-AEF5-4E6F-A900-991953F3BF73Q45962119-75BF5B5E-C418-4A72-BEF4-193F4C7FB28EQ46040536-917240A8-22DD-4D20-ABDC-5C86DE56F486Q46081099-93586FA7-37F6-4D91-B488-6B330011DA21Q46127189-95D4D07A-585E-4CB5-94F9-A014061B779CQ46644330-C2AA3D69-5472-42F6-B3D8-7D405749219EQ46709585-5424FD2F-110C-44AF-826F-9410E47379E4Q46788366-27CF68A9-3C10-4183-94A0-19FC517C7358Q46921924-969B8AEA-C7C9-4D92-B7F6-FFE74BF74C2A
P50
name
David Binns
@en
type
label
David Binns
@en
prefLabel
David Binns
@en